Error loading player: No playable sources found

Technical Seminar - Answering Difficult Biopharmaceutical Questions with Cyclic Ion Mobility Mass Spectrometry

Date
September 24, 2021
This product is not available for individual purchase, but it is available as part of the following products:

Sponsored by Waters Corporation

Biopharmaceutical processing and manufacturing can produce a variety of post-translational modifications (PTMs) that may affect drug efficacy and safety. High resolution mass spectrometry (HRMS) is commonly used to characterize these modifications. The unique design and capability of the SELECT SERIES CYCLIC IMS mass spectrometer allows for innovative and versatile investigation of complex analytes via ion mobility separations and a variety of data acquisition modes (The CYCLIC IMS increases the resolution in the mobility dimension by giving flexibility to the number of passes that analytes are sent around the drift tube for separation. This capability is critical to resolve isobaric species such as aspartic acid peptide isomers (e.g. beta amyloid 1-16). IMSn can be performed by selecting species separated in the cyclic device to send to pre-store for re-injection for further ion mobility separation.

The separation in the mobility dimension also allows for truncated LC run times without losing sequence coverage for complex samples. This is advantageous for HDX (hydrogen deuterium exchange) analysis, as the shorter run time minimizes back-exchange and (improved instrument performance) increases peptide identifications, thereby providing more confidence in inferences on higher order structure.

In addition to the aforementioned benefits, the CYCLIC IMS gives versatility in fragmentation experiments performed in the trap or transfer cells, pre- or post- mobility separation, respectively. An ECD cell can be installed for orthogonal fragmentation experiments. ECD is especially useful for labile modifications such as phosphorylation and glycosylation, as will be discussed for O-glycopeptides of erythropoietin (EPO). One can also employ fragmentation to glycopeptides to produce oxonium ions, which can then be analyzed by ion mobility to probe their gas phase confirmation and therefore distinguish linkage isomers. The benefits of cyclic IMS, including flexibility in experiment design, improved sensitivity, and mass resolution provides the tools needed to answer complex questions in biopharmaceutical characterization.

Moderator

Speaker Image for Colette Quinn
Waters Corporation

Session Speaker

Speaker Image for Samantha Ippoliti
Waters Corporation

Related Products

Thumbnail for Technical Seminar - Large Molecules Get SLIM: Fast and Informative Large Molecule Characterization with High-Resolution Ion Mobility
Technical Seminar - Large Molecules Get SLIM: Fast and Informative Large Molecule Characterization with High-Resolution Ion Mobility
How can High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) address the challenges of large molecule characterization? This seminar will discuss the benefits of HRIM-MS in enhancing structural characterization of large molecule therapeutics, while increasing throughput and reducing reliance on…